Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.

Jason RoszikWei-Lien WangJohn A LivingstonChristina L RolandVinod RaviCassian YeePatrick HwuAndrew FutrealAlexander J LazarShreyaskumar R PatelAnthony P Conley

Published in: Clinical sarcoma research (2017)

We determined that uterine carcinosarcoma, synovial sarcoma, and leiomyosarcoma patients would potentially benefit from PRAME-specific immunotherapies. Tumor escape through loss of antigen presentation needs to be further studied.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
case report
climate change